China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
Executive Summary
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.
Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.